- Home
- ICCC vs ALXO Comparison
ICCC vs ALXO Comparison
Compare ICCC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- ALXO
- Stock Information
- Founded
- ICCC 1982
- ALXO 2015
- Country
- ICCC United States
- ALXO United States
- Employees
- ICCC N/A
- ALXO N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- ALXO Health Care
- Exchange
- ICCC Nasdaq
- ALXO Nasdaq
- Market Cap
- ICCC 60.1M
- ALXO 56.8M
- IPO Year
- ICCC 1987
- ALXO 2020
- Fundamental
- Price
- ICCC $5.66
- ALXO $1.09
- Analyst Decision
- ICCC
- ALXO Strong Buy
- Analyst Count
- ICCC 0
- ALXO 6
- Target Price
- ICCC N/A
- ALXO $3.30
- AVG Volume (30 Days)
- ICCC 7.0K
- ALXO 744.3K
- Earning Date
- ICCC 11-12-2025
- ALXO 11-06-2025
- Dividend Yield
- ICCC N/A
- ALXO N/A
- EPS Growth
- ICCC N/A
- ALXO N/A
- EPS
- ICCC 0.20
- ALXO N/A
- Revenue
- ICCC $28,274,756.00
- ALXO N/A
- Revenue This Year
- ICCC N/A
- ALXO N/A
- Revenue Next Year
- ICCC N/A
- ALXO N/A
- P/E Ratio
- ICCC $28.16
- ALXO N/A
- Revenue Growth
- ICCC 21.75
- ALXO N/A
- 52 Week Low
- ICCC $3.38
- ALXO $0.40
- 52 Week High
- ICCC $7.60
- ALXO $2.26
- Technical
- Relative Strength Index (RSI)
- ICCC 36.97
- ALXO 55.98
- Support Level
- ICCC $5.59
- ALXO $1.01
- Resistance Level
- ICCC $6.42
- ALXO $1.13
- Average True Range (ATR)
- ICCC 0.27
- ALXO 0.11
- MACD
- ICCC -0.06
- ALXO -0.03
- Stochastic Oscillator
- ICCC 4.96
- ALXO 41.94
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.